Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Completed · Phase 2

Conditions studied: Sarcoma, Kaposi, HIV Infections

In brief

To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.

Key facts

Study ID

NCT00001059

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

120

Expected to finish

1998-08-01

Last updated by the study team

2012-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• G-CSF.
• Licensed or Treatment IND-approved antiretrovirals ( AZT, ddI, ddC, d4T ).
• PCP prophylaxis (required if CD4 count < 200 cells/mm3).
• Chemoprophylaxis or maintenance for bacterial infections, candidiasis, MAC, and herpes simplex.
• Up to 14 days of metronidazole.
• Recombinant erythropoietin.
• Patients must have:
• Documented HIV infection.
• Advanced stage Kaposi's sarcoma.
• No active acute opportunistic infection.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Significant pulmonary insufficiency (unless due to pulmonary KS).
• Significant cardiac insufficiency.
• Other active malignancies except for basal or squamous cell carcinoma of the skin or in situ cervical cancer.
• Grade 2 or worse peripheral neuropathy.
• Altered mental status that prevents informed consent.
• Active Mycobacterium tuberculosis.
• Hypersensitivity or allergic reaction to any study drugs or E. coli-derived medications such as filgrastim (G-CSF).
• Concurrent Medication:
• Excluded:
• GM-CSF.
• Drugs associated with peripheral neuropathy (other than approved antiretrovirals and vincristine).
• Multi-drug therapy for active Mycobacterium tuberculosis (although isoniazid and pyridoxine is allowed as treatment for a positive PPD, with permission of study chair).
• Concurrent Treatment:
• Excluded:
• Radiation therapy to study marker lesions.
• Patients with the following prior condition are excluded:
• Neuropsychiatric history.
• Prior Medication:
• Excluded:
• Any anti-KS therapy within 21 days prior to study entry.
• Prior systemic therapy with any anthracycline (including liposomal anthracyclines), vincristine, or bleomycin.
• Any investigational drug (other than those available through Treatment IND and used for FDA-sanctioned purposes) within 14 days prior to study entry.
• PER AMENDMENT 11/29/95:

Where it is running

• Alabama Therapeutics CRS — Birmingham, Alabama, United States
• USC CRS — Los Angeles, California, United States
• UCLA CARE Center CRS — Los Angeles, California, United States
• Ucsf Aids Crs — San Francisco, California, United States
• University of Colorado Hospital CRS — Aurora, Colorado, United States
• Univ. of Miami AIDS CRS — Miami, Florida, United States
• Queens Med. Ctr. — Honolulu, Hawaii, United States
• Univ. of Hawaii at Manoa, Leahi Hosp. — Honolulu, Hawaii, United States
• Northwestern University CRS — Chicago, Illinois, United States
• Rush Univ. Med. Ctr. ACTG CRS — Chicago, Illinois, United States
• Indiana Univ. School of Medicine, Infectious Disease Research Clinic — Indianapolis, Indiana, United States
• Bmc Actg Crs — Boston, Massachusetts, United States
• Beth Israel Deaconess - East Campus A0102 CRS — Boston, Massachusetts, United States
• Massachusetts General Hospital ACTG CRS — Boston, Massachusetts, United States
• Washington U CRS — St Louis, Missouri, United States
• SUNY - Buffalo, Erie County Medical Ctr. — Buffalo, New York, United States
• Memorial Sloan-Kettering Cancer Ctr. — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.